8-K: Pulse Biosciences Q1 2026 Update: Cardiac Trial Enrollment Accelerated

Pulse Biosciences announced Q1 2026 financial results and accelerated enrollment timelines for its pivotal cardiac catheter IDE trial, NANOPULSE-AF.

Summary

• Pulse Biosciences reported Q1 2026 financial results and provided business updates, highlighting progress in its electrophysiology programs.
• The company is prioritizing its nPulse Cardiac Catheter System for AF treatment, with strong clinical data showing high procedural success and durable outcomes.
• Enrollment in the U.S. IDE pivotal trial, NANOPULSE-AF, commenced in early April 2026 and is now expected to be completed in early Q4 2026, an acceleration from previous timelines.
• The NANOCLAMP-AF surgical AF ablation trial is expected to complete enrollment by the end of the first half of 2027.
• Soft tissue ablation efforts generated $0.4 million in revenue, with positive data on thyroid nodule volume reduction.
• First quarter 2026 revenue was $0.4 million, with total GAAP costs and expenses of $19.6 million, resulting in a GAAP net loss of $18.6 million.
• Cash and cash equivalents stood at $68.3 million as of March 31, 2026.
• The company granted inducement options to four new employees in May 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update due to accelerated trial timelines and strong clinical data, despite increased operating expenses and a wider net loss, which are expected for a development-stage company.

Positives

• Accelerated enrollment timeline for the NANOPULSE-AF U.S. IDE pivotal trial, now expected to complete in early Q4 2026.
• Landmark clinical data presented at AF Symposium and Heart Rhythm 2026 demonstrated exceptional procedure efficiency and durable outcomes for the nPulse Cardiac Catheter System.
• Sustained 100% procedural success by Holter monitor at 6 months (95/95 evaluable patients) and 96% at 12 months (51/53) in the European feasibility study.
• 90% Kaplan-Meier estimate of freedom from atrial arrhythmias at 12 months.
• 74% benign thyroid nodule volume reduction rate with no regrowth at 15-22 months follow-up from the nPulse Vybrance system.
• Addition of key leadership with Dr. David Kenigsberg as full-time Chief Medical Officer and Liane Teplitsky as Chief Operating Officer.

Negatives

• Total GAAP costs and expenses increased to $19.6 million in Q1 2026 from $18.0 million in the prior year period.
• GAAP net loss widened to $18.6 million in Q1 2026 from $16.8 million in the prior year period.
• Non-GAAP net loss increased to $16.4 million in Q1 2026 from $11.4 million in the prior year period.
• Cash and cash equivalents decreased to $68.3 million as of March 31, 2026, from $119.3 million as of March 31, 2025.

Risks

• The company's ability to achieve its strategic focus on electrophysiology and accelerate clinical development.
• The effectiveness and safety of the nPulse technology and nPulse Cardiac Catheter System in treating atrial fibrillation and other conditions.
• Potential for actual results to differ materially from forward-looking statements due to known and unknown risks and uncertainties.
• Reliance on the successful completion of pivotal clinical trials (NANOPULSE-AF and NANOCLAMP-AF) and regulatory approvals.
• Market adoption and competition in the electrophysiology and soft tissue ablation markets.

Future Outlook

The company anticipates advancing critical clinical and regulatory milestones to bring its nanosecond PFA technology to patients and physicians globally. Enrollment completion for the NANOPULSE-AF trial is now expected in early Q4 2026, and for the NANOCLAMP-AF trial by the end of the first half of 2027. The company has approximately $60 million available under an ATM program and a $200 million shelf registration statement.

Management Comments

• This was a defining quarter for Pulse Biosciences. We sharpened our strategic focus on electrophysiology based on landmark clinical outcomes that reinforced the durability and efficiency of AF treatment with the nPulse catheter and commenced enrollment in our U.S. IDE pivotal trial of our nPulse Cardiac Catheter System.
• Based on high investigator enthusiasm and early pivotal study progress, we are pleased to update our anticipated enrollment completion timing to early-Q4, 2026.
• The momentum we are building positions us to advance critical clinical and regulatory milestones that will bring the transformative potential of nanosecond PFA technology to patients and physicians globally.
• Ms. Liane Teplitsky joined Pulse Biosciences as Chief Operating Officer and brings a wealth of experience in electrophysiology at this consequential moment of our strategic focus. Her impact on the nPulse Cardiac Catheter program will enable accelerated clinical development, and her impact is already evident through relationships with leading physicians as well as internal and external business leaders.

Industry Context

StockSavvy.ai notes that Pulse Biosciences is strategically prioritizing its nPulse Cardiac Catheter System for atrial fibrillation treatment, leveraging positive clinical data. The acceleration of its U.S. IDE pivotal trial enrollment aligns with industry trends towards more efficient and durable ablation solutions in cardiology.

Comparison to Industry Standards

• The reported 96% procedural success by Holter monitor at 12 months for the nPulse Cardiac Catheter System in the European feasibility study is competitive with established AF ablation technologies, which typically aim for high single-digit to low double-digit recurrence rates.
• The 41-second average total ablation time reported for the NANOCLAMP-AF trial is significantly faster than traditional surgical ablation methods, which can take several minutes per lesion.
• The 74% benign thyroid nodule volume reduction rate achieved with the nPulse Vybrance system is a strong indicator of efficacy in soft tissue ablation, comparable to or exceeding results from other non-thermal ablation techniques in early studies.

Management Changes

Stakeholder Impact

• Shareholders: Potential positive impact from accelerated clinical trial timelines and strong clinical data, which could lead to future product approvals and market penetration. However, increased expenses and net loss may be a concern.
• Employees: Inducement options granted to new employees suggest growth and investment in talent.
• Physicians and Patients: Potential for improved treatment options for atrial fibrillation and thyroid nodules with the nPulse technology.
• Suppliers: Continued demand for disposables and capital equipment related to the nPulse systems.

Next Steps

• Complete enrollment in the NANOPULSE-AF U.S. IDE pivotal trial in early Q4 2026.
• Complete enrollment in the NANOCLAMP-AF U.S. IDE pivotal trial by the end of the first half of 2027.
• Complete enrollment in the first-in-human feasibility study for papillary thyroid microcarcinoma by year-end 2026.
• Host conference call on May 7, 2026, to discuss business updates and financial results.

Key Dates

Recommendation

The company is making significant progress with its core technology and clinical trials, evidenced by accelerated enrollment and positive data. However, the widening net loss, decreasing cash reserves, and the long road to commercialization and profitability warrant a cautious 'hold' rating until further de-risking events occur, such as regulatory approvals and initial commercial traction.

Keywords

Pulse Biosciences, nPulse technology, nanosecond PFA, Atrial Fibrillation, Cardiac Catheter, IDE trial, Q1 2026 Results, Bioelectric Medicine